Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2020-05-05
DOI
10.1080/14728214.2020.1763954
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modification and biomarker development in Parkinson disease
- (2020) Alberto J. Espay et al. NEUROLOGY
- Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
- (2020) Lamia Sid-Otmane et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of zonisamide on L-DOPA–induced dyskinesia in Parkinson's disease model mice
- (2019) Hiromi Sano et al. NEUROCHEMISTRY INTERNATIONAL
- Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia
- (2019) Thomas Müller et al. DRUGS
- Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat
- (2019) Kathryn Lanza et al. PSYCHOPHARMACOLOGY
- Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel
- (2019) Massimo Marano et al. PARKINSONISM & RELATED DISORDERS
- mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
- (2018) Irene Sebastianutto et al. CURRENT OPINION IN PHARMACOLOGY
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Repurposing drugs to treat l -DOPA-induced dyskinesia in Parkinson's disease
- (2018) Tom H. Johnston et al. NEUROPHARMACOLOGY
- mGlu 4 allosteric modulation for treating Parkinson's disease
- (2018) Delphine Charvin NEUROPHARMACOLOGY
- Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease
- (2018) Julia Paik et al. CNS DRUGS
- Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
- (2018) Regina Katzenschlager et al. LANCET NEUROLOGY
- Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going
- (2018) Aldo Quattrone et al. MOVEMENT DISORDERS
- Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism
- (2018) Maricel Gómez-Soler et al. Frontiers in Neuroscience
- Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
- (2018) Susan H. Fox et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
- (2018) Nataša Dragašević-Mišković et al. EXPERT OPINION ON PHARMACOTHERAPY
- Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial
- (2018) Jean-Christophe Corvol et al. PARKINSONISM & RELATED DISORDERS
- Using Wearable Technology to Generate Objective Parkinson’s Disease Dyskinesia Severity Score: Possibilities for Home Monitoring
- (2017) Mehdi Delrobaei et al. IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
- Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study
- (2017) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Personalized medicine in Parkinson's disease: Time to be precise
- (2017) Nataliya Titova et al. MOVEMENT DISORDERS
- New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States
- (2017) Karl Kieburtz et al. MOVEMENT DISORDERS
- Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias
- (2017) Barbara Picconi et al. MOVEMENT DISORDERS
- Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats
- (2017) Mitsuaki Oki et al. NEUROSCIENCE RESEARCH
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Anthony H. V. Schapira et al. JAMA Neurology
- Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences
- (2017) Carsten Buhmann et al. PLoS One
- mGlu5, Dopamine D2and Adenosine A2AReceptors in L-DOPA-induced Dyskinesias
- (2016) Nicolas Morin et al. Current Neuropharmacology
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Long-term effects of rasagiline and the natural history of treated Parkinson's disease
- (2016) Olivier Rascol et al. MOVEMENT DISORDERS
- Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
- (2016) Angelo Antonini et al. MOVEMENT DISORDERS
- GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-upAuthor Response
- (2016) Christos Sidiropoulos et al. NEUROLOGY
- Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease
- (2015) Lisa F. Potts et al. ANNALS OF NEUROLOGY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Trends in inpatient antiparkinson drug use in the USA, 2001–2012
- (2015) James A. G. Crispo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Motor complications in an incident Parkinson's disease cohort
- (2015) N. W. Scott et al. EUROPEAN JOURNAL OF NEUROLOGY
- NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
- (2015) H. Iderberg et al. EXPERIMENTAL NEUROLOGY
- Overlapping binding sites drive allosteric agonism and positive cooperativity in type 4 metabotropic glutamate receptors
- (2015) Xavier Rovira et al. FASEB JOURNAL
- Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease
- (2015) Christiana Ossig et al. JOURNAL OF NEURAL TRANSMISSION
- Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
- (2015) Miho Murata et al. MOVEMENT DISORDERS
- Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease
- (2015) Giovanna Lopane et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
- (2015) Carlo Cattaneo et al. Journal of Parkinsons Disease
- Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
- (2014) R. A. Hauser et al. EUROPEAN JOURNAL OF NEUROLOGY
- Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
- (2014) Marios Politis et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapeutic potential of targeting glutamate receptors in Parkinson’s disease
- (2014) Clare Finlay et al. JOURNAL OF NEURAL TRANSMISSION
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
- (2014) PD MED Collaborative Group LANCET
- The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model
- (2014) Erwan Bezard et al. MOVEMENT DISORDERS
- Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
- (2014) Rupam Borgohain et al. MOVEMENT DISORDERS
- UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
- (2014) Philippe Huot et al. NEUROPHARMACOLOGY
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
- (2014) Christopher Kobylecki et al. PARKINSONISM & RELATED DISORDERS
- Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries
- (2014) Marlene C. Hechtner et al. PARKINSONISM & RELATED DISORDERS
- Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia
- (2014) M. Heiman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deep Brain Stimulation Induces Striatal Dopamine Release in Obsessive-Compulsive Disorder
- (2013) Martijn Figee et al. BIOLOGICAL PSYCHIATRY
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
- (2013) C. Warren Olanow et al. MOVEMENT DISORDERS
- The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model
- (2012) Henrik Ponten et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates
- (2012) Tom H. Johnston et al. FASEB JOURNAL
- Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia
- (2012) Dong-Churl Suh et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial
- (2012) Vincent JJ Odekerken et al. LANCET NEUROLOGY
- Amantadine: The journey from fighting flu to treating Parkinson disease
- (2012) G. Hubsher et al. NEUROLOGY
- MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates
- (2012) Nicolas Morin et al. NEUROPHARMACOLOGY
- Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials
- (2011) Spyridon Spyros Papapetropoulos CNS Neuroscience & Therapeutics
- Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
- (2011) Kristin B. Dupre et al. EXPERIMENTAL NEUROLOGY
- Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia
- (2011) Nina Nevalainen et al. JOURNAL OF NEUROCHEMISTRY
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- (2011) Christopher Kobylecki et al. MOVEMENT DISORDERS
- The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
- (2011) James B. Koprich et al. MOVEMENT DISORDERS
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
- (2010) Fabrizio Stocchi et al. ANNALS OF NEUROLOGY
- Entacapone
- (2010) Thomas Müller Expert Opinion on Drug Metabolism & Toxicology
- Effects of amantadine on circulating neurotransmitters in healthy subjects
- (2010) Fuad Lechin et al. JOURNAL OF NEURAL TRANSMISSION
- Patient perception of dyskinesia in Parkinson's disease
- (2010) S. W. Hung et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
- (2010) T. H. Johnston et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Effect of histamine H2receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
- (2010) Ray L. Watts et al. MOVEMENT DISORDERS
- Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias
- (2010) B. Ouattara et al. NEUROSCIENCE
- l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia
- (2009) Hanna S. Lindgren et al. JOURNAL OF NEUROCHEMISTRY
- Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
- (2009) D. Rylander et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys
- (2009) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats
- (2009) Karen L. Eskow et al. SYNAPSE
- Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- (2008) A. Munoz et al. BRAIN
- Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias
- (2008) Bazoumana Ouattara et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
- (2008) Pedro J. García Ruiz et al. MOVEMENT DISORDERS
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease
- (2008) Naomi P. Visanji et al. NEUROBIOLOGY OF DISEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now